Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention
Cancer Biol Med. 2014 Mar; 11(1): 44–55, doi: 10.7497/j.issn.2095-3941.2014.01.004
Olga B. Garbuzenko,1 Gediminas Mainelis,2,3 Oleh Taratula,1,4 and Tamara Minko1,3,5
Download the PDF from VitaminDWiki
liposomes loaded with doxorubicin
Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges
Asian Journal of Pharmaceutical Sciences. Vol 10, Issue 6, December 2015, Pages 481-489
Wing-HinLee Ching-Yee Loo DanielaTraini Paul M.Young
Ever since the success of developing inhalable insulin, drug delivery via pulmonary administration has become an attractive route to treat chronic diseases. Pulmonary delivery system for nanotechnology is a relatively new concept especially when applicable to lung cancer therapy.
Nano-based systems such as
- polymeric nanoparticles or micelles
are strategically designed to enhance the therapeutic index of anti-cancer drugs through improvement of their bioavailability, stability and residency at targeted lung regions. Along with these benefits, nano-based systems also provide additional diagnostic advantages during lung cancer treatment, including imaging, screening and drug tracking. Nevertheless, delivery of nano-based drugs via pulmonary administration for lung cancer therapy is still in its infancy and numerous challenges are expected. Pharmacology, immunology, toxicology and large-scale manufacturing (stability and activity of drugs) are some aspects in nanotechnology that should be taken into consideration for the development of inhalable nano-based chemotherapeutic drugs. This review will focus on the current inhalable nano-based drugs for lung cancer treatment.
List of medical inhalants Wikipedia
Inhalational anesthetic agents